Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice

scientific article published on 01 March 1994

Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice is …
instance of (P31):
scholarly articleQ13442814

External links are
P698PubMed publication ID7511625

P2093author name stringKioussis D
Meier W
Hochman PS
Majeau GR
Jimmo B
P433issue6
P407language of work or nameEnglishQ1860
P304page(s)2753-2767
P577publication date1994-03-01
P1433published inJournal of ImmunologyQ3521441
P1476titleMechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice
P478volume152

Reverse relations

cites work (P2860)
Q28478230A biophysical model of cell adhesion mediated by immunoadhesin drugs and antibodies
Q73882481A multimeric form of soluble recombinant sheep LFA-3 (CD58) inhibits human T-cell proliferation
Q37686066Advances in immunosuppression for renal transplantation.
Q35868862Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis
Q33757065Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris
Q35834649BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population
Q36827134Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?
Q26824580Cellular targeting in autoimmunity
Q45884948Development and application of a real-time PCR method for pharmacokinetic and biodistribution studies of recombinant adenovirus
Q36688075Disrupted splenic architecture, but normal lymph node development in mice expressing a soluble lymphotoxin-beta receptor-IgG1 fusion protein.
Q59136962Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells
Q37123276High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects.
Q36763565Novel targeted therapies for eosinophilic disorders
Q33530942Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept
Q52007397Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration.
Q35579427Psoriasis treatment: current and emerging directed therapies
Q37196716Receptor-directed therapy of T-cell leukemias and lymphomas
Q39178547Role of Memory T Cells in Allograft Rejection and Tolerance
Q34149246Selective Targeting of Human Alloresponsive CD8+ Effector Memory T Cells Based on CD2 Expression
Q36661303The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis.
Q57177957Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management
Q37600436Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases

Search more.